从非酒精性脂肪性肝病到代谢功能障碍相关脂肪性肝病：脂肪性肝病的更新命名及诊断标准 - Suppr

From NAFLD to MASLD: updated naming and diagnosis criteria for fatty liver disease.

作者信息

Rinella Mary E, Sookoian Silvia

机构信息

Pritzker School of Medicine, University of Chicago, Chicago, IL, USA.

Clinical and Molecular Hepatology, Centro de Investigación Traslacional en Salud, Universidad Maimónides, Buenos Aires, Argentina; Facultad de Ciencias de la Salud, Universidad Maimónides, Buenos Aires, Argentina; Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina.

出版信息

J Lipid Res. 2024 Jan;65(1):100485. doi: 10.1016/j.jlr.2023.100485. Epub 2023 Dec 14.

DOI:10.1016/j.jlr.2023.100485

PMID:38103785

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10824973/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3511/10824973/757b94537047/gr1.jpg

相似文献

From NAFLD to MASLD: updated naming and diagnosis criteria for fatty liver disease.

J Lipid Res. 2024 Jan;65(1):100485. doi: 10.1016/j.jlr.2023.100485. Epub 2023 Dec 14.

Differences in the prevalence of NAFLD, MAFLD, and MASLD according to changes in the nomenclature in a health check-up using MRI-derived proton density fat fraction.

Abdom Radiol (NY). 2024 Sep;49(9):3036-3044. doi: 10.1007/s00261-024-04285-w. Epub 2024 Apr 8.

From NAFLD to MASLD: Promise and pitfalls of a new definition.

J Hepatol. 2024 Jul;81(1):e18-e19. doi: 10.1016/j.jhep.2023.09.038. Epub 2023 Dec 19.

Reply to: "From NAFLD to MASLD: Promise and pitfalls of a new definition'.

Ann Hepatol. 2024 Jul-Aug;29(4):101178. doi: 10.1016/j.aohep.2023.101178. Epub 2023 Dec 19.

From NAFLD to MASLD: Promise and pitfalls of a new definition.

Ann Hepatol. 2024 Jul-Aug;29(4):101179. doi: 10.1016/j.aohep.2023.101179. Epub 2023 Dec 19.

Fibrosis and steatotic liver disease in US adolescents according to the new nomenclature.

J Pediatr Gastroenterol Nutr. 2024 Aug;79(2):229-237. doi: 10.1002/jpn3.12230. Epub 2024 May 1.

Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease.

J Hepatol. 2024 May;80(5):694-701. doi: 10.1016/j.jhep.2024.01.014. Epub 2024 Jan 27.

Reply to: "From NAFLD to MASLD: Promise and pitfalls of a new definition": EASL, AASLD and ALEH stand united to advance the field of steatotic liver disease.

J Hepatol. 2024 Jul;81(1):e20-e21. doi: 10.1016/j.jhep.2023.10.008. Epub 2023 Dec 19.

Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD.

Curr Obes Rep. 2024 Sep;13(3):510-531. doi: 10.1007/s13679-024-00574-z. Epub 2024 May 29.

[NAFLD renaming to MAFLD, MASLD: background, similarities, differences, and countermeasures].

Zhonghua Gan Zang Bing Za Zhi. 2023 Aug 20;31(8):789-792. doi: 10.3760/cma.j.cn501113-20230809-00042.

引用本文的文献

Synergistic Integration of Multimodal Metabolic and Bariatric Interventions Transforming Transplant Care.

J Clin Med. 2025 Aug 11;14(16):5669. doi: 10.3390/jcm14165669.

Eryptosis in Liver Diseases: Contribution to Anemia and Hypercoagulation.

Med Sci (Basel). 2025 Aug 12;13(3):125. doi: 10.3390/medsci13030125.

Ablation of Hepatocyte Derived-FGL1 Does Not Aggravate Metabolic Dysfunction-Associated Steatotic Liver Disease.

FASEB J. 2025 Aug 31;39(16):e70962. doi: 10.1096/fj.202501997R.

Gut microbiome-specific nanoparticle-based therapeutics for liver diseases.

World J Gastroenterol. 2025 Jul 21;31(27):109105. doi: 10.3748/wjg.v31.i27.109105.

Cancer Incidence and Trends in Persistent Poverty Areas of California by Race/Ethnicity and Sex.

Cancer Med. 2025 Aug;14(15):e71088. doi: 10.1002/cam4.71088.

Exploring the role of xanthine oxidase and aldehyde oxidase in metabolic dysfunction-associated steatotic liver disease (MASLD).

J Mol Histol. 2025 Jul 23;56(4):237. doi: 10.1007/s10735-025-10507-2.

Pharmacological inhibition of G protein-coupled receptor kinase 5 decreases high-fat diet-induced hepatic steatosis in mice.

bioRxiv. 2025 Jun 28:2025.06.25.661655. doi: 10.1101/2025.06.25.661655.

New insights into the role of metallothioneins in obesity and diabetes.

Int J Obes (Lond). 2025 Jul 14. doi: 10.1038/s41366-025-01850-1.

Interaction Between Periodontitis and MASLD: Pathophysiological Associations and Possibilities of Prevention and Therapy.

Biomedicines. 2025 May 30;13(6):1346. doi: 10.3390/biomedicines13061346.

Gut microbiota in liver diseases: initiation, development and therapy.

Front Med (Lausanne). 2025 Jun 4;12:1615839. doi: 10.3389/fmed.2025.1615839. eCollection 2025.

本文引用的文献

Prevalence, distribution, and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings.

Hepatology. 2024 Jun 1;79(6):1393-1400. doi: 10.1097/HEP.0000000000000664. Epub 2023 Nov 1.

Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease.

J Hepatol. 2024 Mar;80(3):419-430. doi: 10.1016/j.jhep.2023.11.004. Epub 2023 Nov 18.

Confirmatory biomarker diagnostic studies are not needed when transitioning from NAFLD to MASLD.

J Hepatol. 2024 Feb;80(2):e51-e52. doi: 10.1016/j.jhep.2023.07.017. Epub 2023 Aug 3.

Can we use old NAFLD data under the new MASLD definition?

J Hepatol. 2024 Feb;80(2):e54-e56. doi: 10.1016/j.jhep.2023.07.021. Epub 2023 Aug 2.

A multisociety Delphi consensus statement on new fatty liver disease nomenclature.

Ann Hepatol. 2024 Jan-Feb;29(1):101133. doi: 10.1016/j.aohep.2023.101133. Epub 2023 Jun 24.

A multisociety Delphi consensus statement on new fatty liver disease nomenclature.

J Hepatol. 2023 Dec;79(6):1542-1556. doi: 10.1016/j.jhep.2023.06.003. Epub 2023 Jun 24.

A multisociety Delphi consensus statement on new fatty liver disease nomenclature.

Hepatology. 2023 Dec 1;78(6):1966-1986. doi: 10.1097/HEP.0000000000000520. Epub 2023 Jun 24.

Advances in our understanding of the molecular heterogeneity of fatty liver disease: toward informed treatment decision making.

Expert Rev Gastroenterol Hepatol. 2023 Apr;17(4):317-324. doi: 10.1080/17474124.2023.2191190. Epub 2023 Mar 17.

AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease.

Hepatology. 2023 May 1;77(5):1797-1835. doi: 10.1097/HEP.0000000000000323. Epub 2023 Mar 17.

NAFLD and NASH biomarker qualification in the LITMUS consortium - Lessons learned.

J Hepatol. 2023 Apr;78(4):852-865. doi: 10.1016/j.jhep.2022.11.028. Epub 2022 Dec 14.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

From NAFLD to MASLD: updated naming and diagnosis criteria for fatty liver disease.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献